Compare Fidelity National Information Servcs Inc (FIS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Fidelity National Information Servcs Inc trades at $34.21 (market cap $17.71B), while State Street SPDR S&P Biotech ETF trades at $153.66 (market cap $10.11B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FIS | XBI | |
|---|---|---|
Market Cap | $17.71B | $10.11B |
Volume | 9,047,825 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $68.57 | $169.55 |
52-Week Low | $32.44 | $104.99 |
Typical Hold Time | 88 Days | 37 Days |
Enterprise Value | $38.22B | — |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.19, up 1.09% with bearish technical signals but strong fundamentals including a low P/E of 5.27 and net income margin of 27.65%. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss. The company demonstrates business momentum with multiple core banking wins and product launches, including embedded banking platform and cloud modernization initiatives announced in September 2026.
FIS presents a compelling value opportunity with attractive valuation metrics and improving profitability, though technical indicators suggest near-term pressure. The 37% upside to consensus price target of $47.15 and strong analyst support (57% buy ratings) indicate Wall Street optimism, balanced by debt concerns and competitive fintech landscape requiring careful monitoring.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
